|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Characteristics or Variables | Diprospan group(N=48) | Control group(N=48) | Absolute standardized difference | *P-*value |
| Pathology type of tumor (n [%]) |  |  |  | .. |
| Astrocytoma | 4 (8.3) | 8 (16.7) | Abs. diff. (%): -8.4 | .. |
| Oligodendroglioma | 8 (16.7) | 6 (12.5) | Abs. diff. (%): 4.2 | .. |
| Glioblastoma | 4 (8.3) | 6 (12.5) | Abs. diff. (%): -4.2 | .. |
| Meningoma | 22 (45.8) | 20 (41.7) | Abs. diff. (%): 4.1 | .. |
| Metastasis | 1 (2.1) | 1 (2.1) | Abs. diff. (%): 0 | .. |
| Other | 9 (18.8) | 7 (14.6) | Abs. diff. (%): 4.2 | .. |
| Duration of surgery (min) | 232.2±12.1 | 218.6±12.5 | Mean diff. = 14.4 | 0.438\* |
| Time to extubation (min) | 22.6±1.5 | 21.4±1.8 | Mean diff. = 1.2 | 0.600\* |
| Volume of local infiltration solution (ml) | 21.9±0.4 | 22.5±0.4 | Mean diff. = -0.6 | 0.271\* |
| The total amount of sufentanil consumption (μg) in surgery | 36.9±0.8 | 36.3±0.9 | Mean diff. = 0.6 | 0.629\* |
| The total amount of remifentanil consumption (μg/kg/h)  | 8.2±0.3 | 11.6±0.6 | Mean diff. = -3.4 | <0.001\* |

Values are presented as mean ± standard deviation for continuous data or number (%) for categorical data;

Diprospan group: ropivacaine plus diprospan group; Control group: ropivacaine alone group.

\* two independent samples t-test.